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The human umbilical cord forms a connection between the placenta and the foetus. It is composed of two arteries and one vein
surrounded by Wharton’s jelly. Pre-eclampsia is accompanied by extensive remodeling of extracellular matrix of umbilical cord.
Matrix metalloproteinases (MMPs) are engaged in degradation of extracellular matrix proteins and activation/inactivation of
certain cytokines and enzymes. These enzymes will probably play a central role in the release of matrix-embedded cytokines
and growth factors. MMP-2 (gelatinase A) is the main collagenolytic enzyme of both umbilical artery and vein. Other
metalloproteinases are present in several times lower amounts. Reduced activity of collagen-degrading enzymes may be a factor,
which enhances the accumulation of collagen and some other proteins in the pre-eclamptic umbilical cord tissues. It seems to be
possible that similar alterations occur in other fetal blood vessels. It may result in an increase in peripheral resistance as well as
an increase in the blood pressure in the fetal vascular system. Some observations suggest that the raised pressure may persist after
birth. Pre-eclampsia may be a factor that evokes an initiation of hypertension in utero and its ampliﬁcation through childhood
and adulthood.
1.StructureoftheUmbilicalCord
The human umbilical cord forms a connection between the
placenta and the foetus. It is composed of three blood vessels
of diﬀerent structure and function, one vein, which trans-
ports oxygenated and nutrition-rich blood from placenta to
foetus,andtwoarteries,which transportdeoxygenatedblood
and metabolic waste products from foetus to placenta. All
these vessels are surrounded by Wharton’s jelly [1], which
constitutes the major part of human umbilical cord and
provides a thick protective mantle around vessels. Wharton’s
jelly plays also an important role as a storage for some
compounds, such as growth factors [2].
The extracellular matrix (ECM) in the vascular wall
contains many macromolecules (collagen, elastin, proteo-
glycans, and glycoproteins) necessary for the structural and
functional properties of vessel wall [3]. Proteolysis is a major
process leading to changes in the ECM [4].
2.Remodelingofthe UmbilicalCordin
Pre-eclampsia
2.1. Umbilical Cord Artery. It was found in our studies that
pre-eclampsia is accompanied by an extensive remodelling
of the ECM of the umbilical cord. The umbilical cord
arteries (UCAs) of newborns delivered by mothers with pre-
eclampsia contain more than twice the amount of collagen
andmarkedlylesselastinincomparisontothecorresponding
arteries of newborns delivered by healthy mothers [5]. The
changes in collagen composition are accompanied by an
early reduction of hyaluronic acid and its replacement by
sulphated glycosaminoglycans [6]. Pre-eclampsia-associated
decrease in hyaluronic acid content is a result of a decreased
synthesis of this substance, whereas an increase in sulphated
glycosaminoglycanscontentisratheraresultofslowerdegra-
dation of newly synthesized these compounds [7]. Signiﬁ-
cant reduction in the activities of neutral endoglycosidases2 Journal of Pregnancy
degrading chondroitin 4-sulphate and 6-sulphate, dermatan
sulphate and heparin was found. The activities of main
exoglycosidases (N-acetylhexosaminidase, β-galactosidase,
α-iduronidase, and β-glucuronidase) also decrease [8]. Fur-
thermore,theincrease intheratioofthecontentofsulphated
glycosaminoglycans to the content of the protein core of
proteoglycans of newborns delivered by mothers with pre-
eclampsia was determined. The expression of decorin core
protein was enhanced, whereas biglican expression was
lowered. The high-molecular proteoglycans, for example,
versicanand perlecan obtained for pre-eclamptic UCAswere
less prominent than in the case of control material [9].
The pre-eclampsia-associated alterations in proteoglycans
of the UCAs seem to participate in the rearrangement of
the ECM of this tissue. Along with the pathomorphological
and biochemical changes, they may aﬀect the mechanical
properties of the UCAs and disturb fetal blood circulation
[10].
An increase in tissue collagen content may result from
increasedsynthesis, decreaseddegradation,oracombination
of both phenomena. It was found by metabolic studies
(“pulse-chase” experiment) with the use of 14C-proline that
tissue slices of the UCAs taken from newborns delivered by
mothers with pre-eclampsia incorporate much more of this
amino acid into collagenase-sensitive and hydroxyproline-
containing protein and demonstrate decreased degradation
of newly synthesised collagen in comparison to corre-
sponding slices taken from newborns delivered by healthy
mothers [11]. Also pre-eclamptic serum stimulates collagen
synthesis by human skin ﬁbroblasts growing in vitro [12].
These observations allow concludingthat the pre-eclampsia-
associated increase of collagen content in the UCAs results
from both enhanced synthesis and decreased degradation of
newly synthesised collagen. It is known that the activity of
collagenolytic enzymes is a main factor regulating collagen
degradation rate in tissues.
Arterial hypertension seems be a factor which aﬀects
collagen metabolism in the UCA wall [13–15]. Such a
combination of these two phenomena (induced by hyper-
tension) was described by Bishop et al. [16]. They found
that the experimentally induced pressure overload in the
pulmonary artery of rabbits (reducing the diameter of this
artery by 50%) results in the right ventricular hypertrophy
accompanied with a six-fold increase in collagen synthesis
and a decrease (by half) in collagen degradation rate in the
right heart ventricle. It resulted in more than a two-fold
accumulation of collagen in myocardium after 14 days of
the experiment. In the same time, no signiﬁcant change was
observed in the left ventricle. It seems possible that pre-
eclampsia-associated increase ofcollagencontentintheUCA
may be a result of a mechanism similar to that described
by Bishop et al. [16]. An increase of blood pressure in the
UCA may enhance the biosynthesis of collagen and decrease
its degradation. On the other hand, the remodelling of the
UCAs may be responsible for the decrease in the fetuses
blood ﬂow of women with pre-eclampsia.
Pre-eclampsia-induced accumulation of collagen is
accompanied by a distinct reduction in elastin content in
the UCA wall [17]. The replacement of elastin by collagen
may decrease the compliance of the umbilical cord arteries.
The reduction in compliance can increase the peripheral
resistance, and, inversely, this increased resistance may
modify the umbilical vessels elastin components. It seems to
be possible that similar alterations occur in other fetal blood
vessels. It may result in an increase of peripheral resistance as
well as an increase of the blood pressure in the fetal vascular
system. Some observations suggest that the raised pressure
may persist after birth [18]. One may expect that the pre-
eclampsia associated changes in arterial walls may aﬀect the
vascular system in adulthood. Pre-eclampsia may be a factor
which evokes an initiation of hypertension in utero and its
ampliﬁcation through childhood and adulthood [19].
These phenomena correspond to an early ageing of
these tissues [5, 20]. The accumulation of collagen with
simultaneous decrease in elastin content in the umbilical
cord arteries may reduce the elasticity of arterial wall and
decrease the blood ﬂow in the fetus of woman with pre-
eclampsia.
2.2. Umbilical Cord Vein. We have also found that pre-
eclampsia is accompanied by an extensive remodeling of the
extracellular matrix of the umbilical cord vein (UCV) of
newborns delivered by mothers with pre-eclampsia. It con-
tains less collagen in comparison to the corresponding veins
of newborns delivered by healthy mothers [21]. Further-
more, the change in relationship among collagens of main
types was detected. Pre-eclamptic UCVs contain less type I
collagen and more type III collagen. That polymeric collagen
is less susceptible to the action of depolymerizing agents
[22]. Although the elastin content is higher in pre-eclamptic
UCV, its polymerization is lower [21]. The amounts of
the core proteins of decorin, biglycan, and versican were
distinctly higher in pre-eclamptic veins in comparison to
control vessels [23]. The content of glycosaminoglycans
did not change signiﬁcantly [24], but speciﬁc activities of
neutral endoglycosidases (degrading chodroitin 6-sulphate,
dermatan sulphate, heparin, heparan, and keratan sul-
phate) and main exoglycosidases (N-acetylhexosaminidase,
β-galactosidase, and β-glucuronidase) decreased in pre-
eclamptic vessel [25].
2.3. Wharton’s Jelly. The great remodeling of pre-eclamptic
Wharton’s jelly ECM has been also found. The higher total
content of collagen with its solubility decreased has been
detected. The lower solubility of collagen in pre-eclamptic
tissue may be evoked by a relatively higher proportion in the
amount of type III collagen. Pre-eclamptic Wharton’s jelly
contains higher amounts of glycosaminoglycans in compari-
son to control tissue. Premature replacement of hyaluronic
acid by sulphated glycosaminoglycans has been observed
[26]. Pre-eclampsia is associated with a lower levelof all pro-
teoglycan core proteins, especially those of higher molecular
mass(suchasversican)althoughthesamesetofcoreproteins
were found in normal and pre-eclamptic Wharton’s jelly.
The higher ratio of sulphated glycosaminoglycans to proteo-
glycan core proteins has been detected in this tissue [27].
It can be a result of decrease in their degradation, becauseJournal of Pregnancy 3
of the lower activity of neutral endoglycosidases (degrading
chondroitin 4- and 6-sulphate, dermatan sulphate, heparin,
and heparan sulphate) and two exoglycosidases of main
signiﬁcance (N-acethylhexosaminidase and β-galactosidase)
[28].
3.ProteolyticActivityofthe Umbilical Cord
3.1. Umbilical Cord Artery. It seems that the remodelling of
theumbilicalcordvessels mayberesponsible forthedecrease
of blood ﬂow in the foetus of women with pre-eclampsia
[23, 29, 30]. On the other hand, a reduction of blood ﬂow
in the fetal circulation may be responsible for remodeling
of the umbilical cord vessels. Generally, a reduction of
maternal blood ﬂow to the uterus rather than fetal blood
ﬂow (unless the fetus is small) has been observed in pre-
eclampsia and/or intrauterine growth restriction (IUGR)
[31, 32]. We evaluated whether or not this phenomenon is
associated with alterations in the activities of collagenolytic,
gelatinolytic, and nonspeciﬁc proteolytic enzymes that may
be involved in collagen degradation. The activity ofprolidase
that provides proline as a substrate for collagen biosynthesis
was also investigated.
It is apparent from our studies [13] that the extracts
of both control and pre-eclamptic UCAs demonstrate
signiﬁcant proteolytic activities, especially at neutral pH
range. Albumin is readily digested by UCA-proteases to low-
molecular-mass products.
Neither the control nor the pre-eclamptic UCAs
extracts digested native collagen. Treatment of reconsti-
tuted collagen ﬁbres with UCA-extracts did not aﬀect the
electrophoretic mobility of collagen subunits. Treatment
of UCA-extracts with latent collagenase-activating agents
(trypsin, p-chloromercuric benzoate) did not evoke an
appearance of collagenolyticactivity. Native collagenwas not
degraded in the experimental conditions [13].
In contrast to that, gelatin (denatured collagen) was
digested to low-molecular-mass products by UCA-extracts.
The gelatinolytic activity of crude UCA-extracts was very
low, but it increased many times under the action of trypsin.
It can be concluded that the arterial wall tissue contains a
latentformofgelatinasewhich maybeactivated inatissueby
otherproteolyticenzymes. Pre-eclampsia isassociated with a
distinct decrease of gelatinolytic activity in UCA-wall [13].
Degradation of collagen may occur both intracellularly
(before its secretion) or extracellularly. The “pulse chase”
experiments performed by Bienkowski et al. [33]d e m o n -
strated that the amount of intracellularly degraded collagen
attained a value equal to approximately 20% of the amount
synthesised during the labelling period. Similar observations
werereportedbyAnderssonandWarburton[34].Extracellu-
lar collagen may be internalized by phagocytosis of collagen
ﬁbrils and degraded by some lysosomal proteinases [35].
Interstitial collagens, the most abundant protein of
connective tissue, are degraded by speciﬁc collagenolytic
enzymes.Productsofcollagenolysisdenatureatphysiological
temperature and become susceptible to the action of gelati-
nases and other nonspeciﬁc proteases.
3.2. Umbilical Cord Vein. A signiﬁcant role in collagen
degradation in the UCV wall is attributed to gelatinase
A (MMP-2) [36, 37]. That enzyme is capable of cleaving
soluble, triple helical type I collagen. It is of interest
that zymography demonstrates the presence of gelatinolytic
activity in control UCV extracts, even those not treated with
p-aminophenylmercuric acetate (APMA). The gelatinolytic
activity observed on the zymogram may be a result of the
activating action of sodium dodecyl sulphate (SDS) on the
latent form of gelatinase A [38]. The treatment of proge-
latinases with APMA causes a conformational alteration that
allows a stepwise autolytic cleavage of the propeptide from
latent enzymes [38]. Such cleavage results in the activation
of progelatinases. The crudeextracts ofcontrol UCV contain
only a trace of actual collagenolytic activity, but its potential
activity is distinctly visible. The action of trypsin on control
UCV extract resulted in an increase in the degradation of
reconstituted collagen ﬁbres at least 7 folds. In contrast to
these ﬁndings in control material, it was not able to detect
either actual or potential collagenolytic activity in the pre-
eclamptic vein [29].
The actual gelatinolytic activity of crude UCV extracts
was low, but potential activity (induced by trypsin) is dis-
tinctly apparent. This allows us to conclude that the venous
wall tissue contains a latent form of gelatinase, which may be
activated by tissue proteolytic enzyme(s). One maximum of
activity observed at pH 7.5 seems to correspond to gelatinase
A, which was detected by zymography. Its activity was lower
in the pre-eclamptic vein. The other maximum of activity
was detected in the slightly acidic pH range (pH 6.0–6.5).
This must be due to a diﬀerent enzyme or mixture of
enzymes. Pre-eclampsia is associated with a distinct decrease
in the activity of this/these enzyme/s. Albumin is readily
digested by UCV-proteases to low-molecular-mass products.
The extracts of control UCVs demonstrate signiﬁcant actual
and total proteolytic activities, especially within a neutral
pH range. It is of interest that both the actual and total
proteolytic activities of pre-eclamptic UCV extract, at a
neutral pH range, were distinctly lower in comparison to the
control [29]. These nonspeciﬁc proteases may contribute to
the degradation of collagenolysis products to low molecular
peptides.
It is not possible to say whether the lower potential
activities of collagenolytic and gelatinolytic enzymes, as
well as those of nonspeciﬁc proteases, may promote an
accumulation of collagen in the pre-eclamptic UCV wall.
In our earlier studies, we observed a reduction of collagen
content in pre-eclamptic umbilical cord veins [21].
The latent forms of proteolytic enzymes do not probably
contribute to collagen degradation in the investigated veins.
Two phenomena of the mechanism of reduction in the
potential activities of the investigated enzymes should be
taken into account. One of them may be a toxic eﬀect of
pre-eclampsia on ﬁbroblasts or other cells [39]. The other
may be an increase in Tissue Inhibitor of Metalloproteinases
(TIMPs) that reduce the collagenase, gelatinase, and proli-
dase as well as nonspeciﬁc proteinase activities [40–42].
It seems that pre-eclampsia-associated decrease of colla-
gen content in the pre-eclamptic vein may be evoked by a4 Journal of Pregnancy
reduction in collagen biosynthesis. This reduction may be
connected with low prolidase activity in the pre-eclamptic
veins [29]. Prolidase [E.C.3.4.13.9] is a cytosolic exopep-
tidase, cleaving imidodipeptides with C-terminal proline
[42, 43]. The biological function of this enzyme involves the
degradation of collagen peptides and the recycling of proline
from imidodipeptides for collagen resynthesis. According
to Jackson et al. [44], the eﬃciency of proline recycling
from imidodipeptides is about 90%. It is possible that an
absence of prolidase severely impedes the eﬃcient recycling
of collagen proline. Prolidase may regulate the turnover of
collagen and may be a rate-limiting factor in the regulation
of collagen production. The low activity of prolidase in the
pre-eclamptic vein may be a factor which reduces collagen
biosynthesis by ﬁbroblasts contained in this vein.
3.3. Wharton’s Jelly. I tc a nb es e e nf r o mt h eo u rr e s u l t st h a t
the collagen content is higher in pre-eclamptic Wharton’s
jelly than in control tissue when calculated per gram of
fresh, wet tissue [45]. Such a phenomenon disappears after
dehydration of Wharton’s jelly of both origins [6, 46–
48]. The diﬀerences are probably associated with various
hydration degrees as a consequence of diﬀerent amounts
of hyaluronic acid that is a strongly hydrophilic substance.
Wharton’s jelly of newborns delivered by mothers with pre-
eclampsiacontainslesshyaluronicacidtherefore;itbindsless
water than the control tissue [46–48]. For this reason, the
proportional amount ofcollagen in pre-eclamptic Wharton’s
jelly is signiﬁcantly higher.
The gelatinolytic activity in control and pre-eclamptic
samples of Wharton’s jelly, measured by the assay of
hydroxyproline in gelatine degradation products, is very low.
The action of trypsin results in a signiﬁcant increase in this
activity. The eﬀect of trypsin was similar in both tissues.
The control extracts demonstrate two peaks of gelatinolytic
activity in a wide pH range, whereas the pre-eclamptic tissue
demonstrates one peak only at pH 7.0. Zymographic analysis
of control and pre-eclamptic Wharton’s jelly demonstrates
diﬀerent electrophoretic patterns of gelatinolytic enzymes.
The zymography allowed to evaluate both the active and
latent forms of gelatinases, which diﬀerin molecular weights
(about 10kD). Control Wharton’s jelly contains two latent
formsofgelatinolyticenzymes: gelatinase A(MMP-2, 72kD)
and gelatinase B (MMP-9, 92kD). The trace 62-kD band is
associated with an active form of gelatinase A. In contrast
to control tissue, the main gelatinolytic enzyme of pre-
eclampticWharton’sjellyisgelatinaseA(MMP-2)[45]ofthe
molecular weight about 72kD [38, 49, 50]. Prolidase from
control Wharton’s jelly extracts releases about 40nmol of
proline per minute per milligram of protein. Pre-eclampsia
does not aﬀect prolidase activity in Wharton’s jelly [45].
The weak gelatinolytic activity measured by the assay of
hydroxyproline released from gelatine allows conclusion that
Wharton’s jelly contains mainly latent forms of gelatinase.
They may be activated in this tissue by other proteolytic
enzymes. The action of trypsin resulted in a signiﬁcant
increase in gelatinolytic activity, which seems to result from
conversion of latent gelatinases into an active enzyme [38,
51].
It is apparent from our studies [45] that the extracts
of both control and pre-eclamptic samples of Wharton’s
jelly demonstrate signiﬁcant proteolytic activities, especially
at neutral pH. This activity distinctly increases after pre-
treatment with trypsin. Proteolytic enzymes are synthesized
in proenzyme forms. Their conversion into active enzymes
requires a limited proteolysis of inactive precursors. Such
an eﬀect may be achieved in vitro by the action of trypsin
[13, 51].
The distinct reduction in gelatinase activity in pre-
eclamptic Wharton’s jelly can be elucidated that gelatinase
forms an inactive complex with one of TIMPs. Such a
complex dissociates under the action of trypsin or sodium
dodecyl sulphate. The decrease in gelatinolytic activity of
Wharton’s jelly may be a factor that reduces the breakdown
of collagen and promotes an accumulation of this protein
[13, 47, 52].
3.4. Matrix Metalloproteinase-1. The UCA wall contained
MMP-1 (collagenase1).Control UCAextractsdemonstrated
low amount of that enzyme, only about 6mg per kg of
protein. Pre-eclampsia was associated with almost two-fold
decrease in MMP-1 (collagenase 1) contentin comparison to
control UCA. The actual activity of MMP-1 (collagenase 1)
in control UCA extracts was low, and in pre-eclamptic UCAs
it was twice lower. Activation with trypsin allowed us to
determine total MMP-1 activity. The UCA extracts (control
and pre-eclamptic) treated with trypsin demonstrated an
increase in MMP-1 activity. Total MMP-1 activity in pre-
eclamptic UCAs extracts was about 30% lower than in
control artery extracts. The eﬀect of trypsin on the pre-
eclamptic extract resulted in two-fold increase in MMP-1
total activity in comparison to its actual activity. But even
such an increase in collagenase 1 activity in pre-eclamptic
UCAsdidnotpermittoreachtheactivityobservedincontrol
UCAs [53].
The comparison of content, actual (nonactivated) and
total (activated with trypsin) speciﬁc activities of MMP-1
in UCA wall slices, incubated in the medium with control
UC serum or pre-eclamptic UC serum, indicated that pre-
eclamptic serum exerted an inhibitory eﬀect on content and
activity of collagenase-1 in that tissue. High concentration of
TIMP-1 in pre-eclamptic-serum-treated tissue (and in lesser
degree TIMP-2) might be one (probably the main) factor,
which inhibited MMP-1 activity [54].
MMP-1 was presented also in the UCV wall at low
amount. Control material contained about 4mg of collage-
nase 1 per kg of protein. Pre-eclampsia was accompanied
with 30%increase in itscontent.Theactualactivityof MMP-
1 in both control and pre-eclamptic UC vein extracts was
similar to that of UCAs. Action with trypsin did not change
the activity of collagenase 1. It suggested that the whole
e n z y m ew a si na c t i v ef o r mi nc ontrol UCV. Pre-eclamptic
material demonstrated 20% higher total activity of MMP-1
in comparison to control (data not published).
3.5. Gelatinases (MMP-2 and MMP-9). MMP-2 (gelatinase
A) and MMP-9 (gelatinase B) are metalloproteinases that
digest denatured collagen to low molecular products [55].Journal of Pregnancy 5
Both collagenases and gelatinases may be inhibited by
the action of TIMPs. Aimes and Quigley [56]f o u n dt h a t
gelatinase A, free of TIMPs is capable of cleaving soluble,
triplehelicaltypeIcollagengeneratingthe3/4and1/4length
collagen fragments characteristic of vertebrate interstitial
collagenases. Both gelatinases participate in degradation of
other ECM components like proteoglycans, elastin, and
structural glycoproteins. Furthermore, MMP-2 can convert
pro-MMP-9 into active enzyme [57]. A signiﬁcant role in
collagen degradation is attributed to MMP-2 (gelatinase A)
[37, 56].
3.5.1. MMP-2. The content of MMP-2 in UCA extracts
were the highest in comparison to other metalloproteinases.
Control material contained 75mg MMP-2 per kg of protein.
Pre-eclampsia was associated with a distinct decrease in
t h ea m o u n to ft h i se n z y m e .I tw a s4 8m go ft o t a lM M P - 2 .
Determination of the active form of gelatinase A indicated
thatpre-eclampsiainducesadecrease intheamountofactive
form of that enzyme from 11mg/kg protein in control UCA
extract to about 8mg/kg protein. However, there was no
diﬀerence in percentage of active form in relation to total
MMP-2 content (15% in control and 16% in pre-eclamptic
UCA extract) [53].
The high amount of total gelatinase A was detected—
about 55mg/kg of protein in the extracts from the UCV wall
of newborns delivered by healthy mothers. Pre-eclampsia
was associated with a decrease in MMP-2 total content—
to about 38mg/kg of protein. Active form of that enzyme
was presented in less than 10% of total amount. UCV wall
of control newborns contained about 4mg of active MMP-2
and pre-eclamptic venous wall contained about 2mg per kg
of protein. The percentage of active form in relation to total
MMP-2 content was twice lower in UCV in comparison to
UCA. It was 8% in control material and 6% in pre-eclamptic
tissue. MMP-2 is the main collagenolytic enzyme in UCVs
wall [58].
Gelatin (denatured collagen) was evidently degraded
by UCA extracts at a wide pH range. The zymogram
demonstrated the presence of gelatinolytic enzyme(s) in the
extracts of both control and pre-eclamptic UCAs. It was of
interest that such an activity was clearly apparent, even in a
crude UCA extract, nontreated with any activating agents.
The control UCA extract demonstrated two lysis bands. The
upper band (latent form of MMP-2) was distinctly visible.
The lower one (active form of MMP-2) was faint. The
activationofcontrolUCAextractwithAPMAdidnotchange
the electrophoretic mobility of gelatinolytic enzyme(s), but
it was observed a partial loss of upper band and increase
in intensity of lower band. Such a change indicated partial
degradation of latent form of the enzyme to the active
formwithlowermolecularmass. Pre-eclampticnonactivated
extract and extract activated with APMA showed a similar
pattern as the control [53].
Similar results were observed for control and pre-
eclamptic UCV extracts nonactivated and activated with
A P M A .H o w e v e r ,t h ea c t i v a t i n ge ﬀect of APMA was dis-
tinctly lower for pre-eclamptic venous extract in comparison
to control [29].
3.6. Matrilysins (MMP-7 and MMP-26). MMP-7 can
degrade insoluble elastin and other vascular basement mem-
brane components. This enzyme participates in activation of
diﬀerent MMPs [59] .H u m a np r o - M M P - 1a n d- 2a n dc a nb e
activated by MMP-7.
MMP-26 is an enzyme with higher speciﬁcity than
MMP-7. MMP-26 selectively cleaved type I gelatine and α1-
proteinaseinhibitor[60];however,itdidnotdigestcollagens,
laminin, elastin, β-casein, plasminogen, or soybean trypsin
inhibitor [61]. The release of MMPs from endothelial
cells may be regulated by variety of factors, for example,
ﬁbronectin, vascular endothelial growth factor (VEGF), and
other cytokines [60]. The proteolytic activity of MMPs is
precisely regulated by the action of zymogen—activating
enzymes and antiproteases. Both MMP-26 and MMP-7 can
activate MMP-9 but their cleavage sites in pro-MMP-9
are diﬀerent. MMP-26 do not cleave pro-MMP-2; another
gelatinase, indicating that pro-MMP-9 activation by MMP-
26, is highly selective [62]. These two MMPs show an
increased expression in a variety of tumours and other
pathologically altered tissues [59, 60].
3.6.1. Matrilysin-1 (MMP-7). Human umbilical cord tissues
contained MMP-7. Free form of that enzyme was detected
in UCA and UCV walls extracts. Indicated molecular weight
of (28kDa) corresponds to free precursor form of this
enzyme. Furthermore, high molecular weight complexes
containing that metalloproteinase were detected in all UC
tissues. The action of dithiothreitol resulted in a release of
severalcompoundsreacting withanti-MMP-7 antibodywith
lower molecular weights, but no free forms of MMP-7 were
detected in control and pre-eclamptic Wharton’s jelly [63].
Those compounds may be complexes of this enzyme with
other ECM components.
Immunoenzymatic assay indicated that pre-eclampsia
was accompaniedby asigniﬁcant increase of MMP-7 content
in UCA and UCV walls. There is not change of MMP-
7 content in pre-eclamptic Wharton’s jelly in comparison
to control subjects. Zymographic analysis demonstrates a
detectableactivityofMMP-7 inallcontrolandpre-eclamptic
UC tissues at positions corresponding to complex form of
this enzyme with other components. It was not found any
casein degradation at position for free active or latent form
of described matrilysin. Clear band at position of 54.3kDa
corresponds to complex of MMP-7 with probably TIMP-1
or TIMP-2. The band with higher molecular mass (about
94.9kDa)shows proteolyticactivity ofMMP-7 complexwith
other ECM components [63].
3.7. Membrane-Type Matrix Metalloproteinases (MT-MMPs).
It was found that UC vessels and Wharton’s jelly of control
and pre-eclamptic newborns contained MT-MMPs. Quanti-
tative assays of MT-MMPs showed signiﬁcant diﬀerences of
their amount in pre-eclamptic UC components. The content
of respective MT-MMP in control tissue was equal to 100%.
The amount of MT-1 and MT-2 in pre-eclamptic UCA
increased to 174% and 309% of control tissue, respectively.
There was not change of MT-5 content in that tissue (107%6 Journal of Pregnancy
Table 1: Matrix metalloproteinases of umbilical cord tissues in pre-eclampsia (n = 10, ∗P<. 05, ∗∗P<. 01, ∗∗∗P<. 001).
Matrix metalloproteinase Umbilical cord artery Umbilical cord vein Wharton’s jelly
control Pre-eclamptic control pre-eclamptic control pre-eclamptic
collagenase
MMP-1 [mg/kg protein] 5.76 3.19∗∗∗ 3.72 4.47∗ ——
stromelysin
MMP-3 [mg/kg protein] 1.08 1.06 0.602 0.778∗∗ ——
gelatinase
MMP-2 [mg/kg protein] 75.4 48.0∗∗∗ 54.8 37.6∗∗∗ ——
MMP-9 [mg/kg protein] 0.444 0.639∗∗∗ 0.419 0.708∗∗∗ ——
matrilysin
MMP-7 [mg/kg protein] 0.258 0.365∗∗∗ 0.439 0.512∗ 1.663 1.682
MMP-26 [% of control] 100 92.4 100 72.7∗∗ 100 128.7∗∗
Membrane-Type MMP
MT-MMP-1 [% of control] 100 174∗∗∗ 100 157∗∗∗ 100 53∗∗∗
MT-MMP-2 [% of control] 100 309∗∗∗ 100 217∗∗∗ 100 183∗∗∗
MT-MMP-3 [% of control] 100 52∗∗∗ 100 60∗∗∗ 100 299∗∗∗
MT-MMP-5 [% of control] 100 107 100 240∗∗∗ 100 94
of control). Pre-eclamptic UCAs contained less amount of
MT-3, only 52% of control. Pre-eclampsia was associated
with an increase in MT-1, MT-2, and MT-5 content in
UCV (157%, 217%, and 240% of control, resp.). Only
amount of MT-3 was reduced to 60% in pre-eclamptic
vein. Signiﬁcant increase in MT-2 and MT-3 content of
pre-eclamptic Wharton’s jelly was found (183% and 299%
of control, resp.). The amount of MT-5 was almost the
same, 94% of control. MT-1 content was decreased in
pre-eclamptic Wharton’s jelly to 53% of control (data not
published).
Western immunoblot experiments showed that human
UC tissue extracts reacted with anti-MMP-14 and anti-
MMP-15 antibody. Free form of both investigated MMPs
was detected in all investigated tissue extracts. Indicated
molecular weight of them (about 54kDa) corresponds to
free active form of respective MMP [57]. Furthermore, high
molecular weight complexes containing these metallopro-
teinases were detected in all UC tissues, with molecular
weight about 200kDa, 115kDa, and 95kDa. They could
be complexes of respective MT-MMP with TIMPs and
some ECM components. It is of interest that the action of
reducing agent on these complexes resulted in a decrease
in their molecular weights. The bands with high molecular
mass (200kDa and 115kDa) disappeared. The band of
the molecular weight 56kDa reacting with anti-MMP-14
antibody was more intensive. A band corresponding to free
MMP-15disappeared.Theactionofdithiothreitolresultedin
a release of a compound with molecular mass about 30kDa
reacting with anti-MMP-14 and anti-MMP-15 antibody.
Those compounds might be a soluble fragment of respective
MT-MMP (data not published).
Table 1 summarizes MMP content in control and pre-
eclamptic umbilical cord tissues.
4.Conclusions
Human umbilical cord tissues contain matrix metallopro-
teinases. The MMPs and their tissue inhibitors (TIMPs) are
engaged in metabolism of extracellular proteins resulting
in the ECM remodelling of UC tissues. MMP-2 exerts
the highest content in UC vessels. Its amount is several
times higher than other MMPs. Gelatinase A is the main
collagenolytic enzyme of both kind of UC vessel wall.
Pre-eclampsia causes a decrease in MMP-2 content in
UCAs and UCV. On the other hand, pre-eclamptic UC
tissues exert changes in the content of other gelatinase,
collagenase, matrilysins, and MT-MMPs, but their inﬂuence
on protein metabolism in ECM seems to be minimal.
We expected that reduced activity of collagen-degrading
enzymes might beafactor, which enhances theaccumulation
of collagen and some other proteins in the UC tissues.
Matrix metalloproteinases may be regulated by humoral
factor(s) circulating in the umbilical cord plasma. It was
described that these factors (especially IGF-1) are regulators
of collagen and other proteins metabolism. IGF-1 has been
found to stimulate collagen synthesis [64–67]a n dt oi n h i b i t
the expression of MMP-1, MMP-3, MMP-8, and MMP-13
[64].
There are some diﬃculties and/or limitation in studying
MMPs including separated determination of active and
latent forms of those enzymes in umbilical cord and other
tissues. Up to date, there are not commercially provided
speciﬁcsubstratesforparticularMMPactivitymeasurement.
Zymographic technique can be used only for those MMPs
(like MMP-2 and MMP-9) that are present in high enough
amounts. Low amounts of MMPs cannot be visualized by
that method. Lack of commercial ELISA kits as well as
lack of speciﬁc antibodies for detection of latent/active formJournal of Pregnancy 7
by Western immunoblot technique or for self-made ELISA
kits also limits the study. Because of those limitations, it is
diﬃcult to evaluate unequivocally their functional activities.
It seems to be possible that similar alterations occur in
other fetal blood vessels. It may result in an increase in
peripheral resistance as well as an increase in the blood
pressure in the fetal vascular system. Some observations
suggest that the raised pressure may persist after birth [68].
One may expect that the pre-eclampsia associated alterations
ofmetalloproteinases activity in blood vessel walls may aﬀect
the vascular system in adulthood. Pre-eclampsia may be a
factor that evokes an initiation of hypertension in utero and
its ampliﬁcation through childhood and adult life.
Future investigations can be focused on engagement
of other enzymes important in remodeling of extracellular
matrix of umbilical cord tissues, like cysteine proteases,
serine proteases, and other metalloproteinases, for example,
ADAMTS/ADAMmetalloproteinases.
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